47400 
Federal Register / Vol. 55, No. 219 / Tuesday, November 13, 1990 ■/ Notices ' 
his intention to submit a human gene 
transfer protocol to the Human Gene 
Therapy Subcommittee and the 
Recombinant DNA Advisory Committee 
for formal review and approval. The title 
of this protocol is; 
“The Administration of Interleukin-2, 
Interleukin-4, and Tumor Infiltrating 
Lymphocytes to Patients with 
Melanoma." 
III. Addition to Appendix D of the “NIH 
Guidelines" Regarding a Human Gene 
Transfer Protocol/Dr. Cometta 
In a letter dated July 25, 1990, Dr. Ken 
Cometta of the University of 
Wisconsin/Madison indicated his 
intention to submit a human gene 
transfer protocol to the Human Gene 
Therapy Subcommittee and the 
Recombinant DNA Advisorj' Committee 
for formal review and approval. The title 
of this protocol is: 
BMT 9049 — ^Retro\Tral-Mediated Gene 
Transfer of Bone Marrow Cells During 
Autologous Bone Marrow Transplantation for 
Acute Leukemia; Understanding Disease 
Recurrence. 
IV. Other Matters To Be Considered by 
the Conunittee ^ 
Protocols which are approved by the . 
Human Gene Therapy Subcommittee 
will be forwarded to the Recombinant 
DNA Advisory Committee for 
consideration during their February 4, 
1991, meeting. 
Attendance by the public will be 
limited to space available. Members of ■ 
the public wishing to speak at this 
meeting may be given such opportunity 
at the discretion of the Chair. 
Dr. Nelson A. Wivel, Director, Office 
of Recombinant DNA Activities, 
National Institutes of Health, Building 
31, room 4BH,. Bethesda, Maryland 
20892, telephone (301) 496-9838, fax 
(301) 496-9839, will provide materials to 
be discussed at this meeting, roster of 
committee members, and substantive 
program information. A summary of the 
meeting will be available at a later date. 
OMB’s “Mandatory Information 
Requirements for Federal Assistance 
Program Announcements" (45 FR 39592, 
June 11, 1980) requires a statement 
concerning the official govemiiient 
programs contained in the Catalog of 
Federal Domestic Assistance. Normally 
NIH lists in its announcements the 
number and title of affected individual 
programs for the guidance of the public. 
Because the guidance in this notice 
covers not only virtually every NIH 
program but also essentially every 
Federal research program in which DNA 
recombinant molecule techniques could 
be used, it has been determined not to 
be cost effective or in the public interest 
to attempt to list these programs. Such a 
list would likely require several 
additional pages. In addition, NIH could 
not be certain that every Federal 
program would be included as many 
Federal agencies; as well as private 
organizations, both national and 
international, have elected to follow the 
NIH Guidelines. In lieu of the individual 
program listing, NIH invites readers to 
direct questions to the information 
address above about whether individual 
programs listed in the Catalog of 
Federal Domestic Assistance are 
affected. 
Dated: November 6, 1990. 
Betty J. Beveridge, 
Committee Management Officer, NIH. 
(FR Doc. 90-26663 Filed 11-0-90; 8:45 am] 
BILLING CODE 4140-01-M 
Planning Subcommittee of the 
Recombinant DNA Advisory Commiee; 
Meeting 
Pursuant to Public Law 92-463, notice 
is hereby given of a meeting of the 
Planning Subcommittee (a subcommittee 
of the Recombinant DNA Advisory 
Committee) on December 6, 1990. The. 
meeting will be held at the National 
Institutes of Health (NIH), Building 3lC, 
Conference room 9, 9000 Rockville Pike, 
Bethesda, Maryland 20892, starting at 
approximately 9 a.m. to adjournment at 
approximately 5 p.m. 
The meeting will be open to the public 
to discuss the following proposed action 
imder the NIH Guidelines for Research 
Involving DNA Molecules (51 FR 16958, 
May 7, 1986): 
I. Results of Regional Hearings 
The subcommittee will consider in 
detail the results of the regional 
hearings. Based on these findings, a ~ 
series of recommendations will be made 
concerning: 
1. Changes in the defintion of 
recombinant DNA; 
2. Review of experiments that involve 
deliberate transfer of drug resistance to 
microorganisms, and cloning of genes 
for biosysnthesis of vertebrate toxins: 
3. Consideration of relinquishing 
review of experiments involving 
environmental release of genetically 
modified organisms; 
4. Educational role of the 
Recombinant DNA Advisory Committee 
and its Human Gene Therapy 
Subcommittee with regard to human 
gene therapy protocols; and 
5. Other changes in the NIH 
Guidelines 
The Planning Subcommittee will 
report with recommendations to the 
Recombinant DNA Advisory Committee 
during their meeting on Februaiy 4, 1991. 
II. Other Matters To Be Considered by 
the Committee 
Attendance by the public will be 
limited to space available. Members of 
the public wishing to speak at this 
meeting may be given such opportunity 
at the discretion of the Chair. 
Dr. Nelson A. Wivel, Director, Office 
of Recombinant DNA Activities, 
National Institutes of Health, Building 
31, room 4B11, Bethesda, Maryland 
20892, telephone (301) 496-9838, fax" 
(301) 496-9839, will provide materials to 
be discussed at this meeting, roster of 
committee members, and substantive 
program information. A summary of the 
. meeting will be available at a later date. 
OMB’s “Mandatory Information 
Requirements for Federal Assistance 
Program Aimouncements" (45 FR 39592. 
June 11, 1980) requires a statement 
concerning the official government 
programs contained in the Catalog of 
Federal Domestic Assistance. Normally 
NIH lists in its announcements the 
number and title of affected individual 
programs for the guidance of the public. 
Because the guidance in this notice 
covers not only virtually every NIH 
program but also essentially every 
Federal research program in which DNA 
recombinant molecule techniques could 
be used, it has been determined not to 
be cost effective or in' the public interest 
to attempt to list these programs. Such a 
list would likely require several 
additional pages. In addition, NIH could 
not be certain that every Federal 
program would be included as many 
Federal agencies, as well as private 
organizations, both national and 
international, have elected to follow the 
NIH Guidelines. In lieu of the individual 
program listing, NIH invites readers to 
direct questions to the information 
address above about whether individual 
programs listed in the Catalog of 
Federal Domestic Assistance a re 
affected: 
Dated: November 6, 1990. 
Betty J. Beveridge, 
Committee Mangement Officer, NIH. 
[FR Doc. 90-26664 Filed 11-9-90; 8:45 am] 
BILLING CODE 414O-01-M 
Recombinant DNA Research, Volume 14 
[367] 
